Company: INTS
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001567264-25-000010
Chunk: 25

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 16
Chunk 25
---
 of up to 3,000,000 shares of common stock. Upon adoption of the 2021 Plan, no more shares would be issued under the 2013 Plan. Starting on January 1, 2022, the shares authorized under the 2021 Plan shall have an annual increase of the lessor of (a) 3.5% of the aggregate number of shares of Common Stock outstanding on the final day of the preceding calendar year, or (b) such smaller amount as determined by the Board. On January 1, 2023 and January 1, 2024, an additional 238,700 and 479,828 shares, respectively, were authorized under the 2021 Plan. As of December 31, 2024, 1,881,649 shares were available for issuance under the 2021 Plan.

F-13

The Company recorded total stock-based compensation in its Statements of Operations as follows (in thousands):Years Ended December 31,20242023Research and development$1,240 $714 General and administrative1,833 684 Total stock-based compensation expense$3,073 $1,398 Stock optionsThe following table summarizes the range of assumptions used to estimate the fair value of stock options issued in 2024 and 2023:20242023Stock price$3.44 to $5.19$2.82 to $6.88Exercise price$3.44 to $5.19$2.82 to $6.88Expected volatility97.06 to 102.16%97.06% to 99.74%Risk free interest rates4.07 to 4.46%3.87% to 4.97%Expected term (years)5 to 75.75 to 6.25For the years ended December 31, 2024 and 2023, a dividend yield of 0% was used because the Company has not historically paid and does not intend to pay a dividend on Common Stock in the foreseeable future. The expected stock price volatility assumption was estimated based on the historical volatilities for industry peers, as the Company had no active market for its stock prior to the IPO and limited history for issuance price of its stock. The risk-free rate assumption is determined using the yield currently available on U.S. Treasury zero coupon issues with a remaining term commensurate with the expected term of the award. The expected term of the option represents the period the options are expected